Clinical Trials Logo

Clinical Trial Summary

To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).


Clinical Trial Description

Per DMC recommendation, the study was terminated early (31Oct2013) due to low enrollment and low endpoint accumulation rate. No safety concerns were involved in the decision to terminate the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00585312
Study type Interventional
Source Pfizer
Contact
Status Terminated
Phase Phase 3
Start date September 2006
Completion date October 2013

See also
  Status Clinical Trial Phase
Completed NCT03095703 - Sirolimus and Familial Adenomatous Polyposis (FAP) Phase 2
Completed NCT03649971 - A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT05014360 - A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT01604564 - Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02113202 - Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Phase 1
Withdrawn NCT03027401 - Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Terminated NCT00140894 - A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Phase 4
Active, not recruiting NCT01187901 - A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Phase 2
Recruiting NCT00319007 - Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Phase 2
No longer available NCT04948398 - Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis